Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

WIIK PHARMA ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.1% 1.1%   Bankruptcy risk   4.3% 3.5% 3.8% 2.9% 2.7% 2.0% 16.0% 16.0%   Credit score (0-100)   49 54 51 57 60 68 12 12   Credit rating   BBB BBB BBB BBB BBB A BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   2,143 2,537 3,403 3,172 4,088 6,666 0.0 0.0   EBITDA   972 1,123 1,776 1,343 1,379 3,726 0.0 0.0   EBIT   972 1,123 1,776 1,343 1,379 3,726 0.0 0.0   Pre-tax profit (PTP)   956.0 1,069.0 1,741.9 1,283.3 1,330.6 3,592.6 0.0 0.0   Net earnings   736.4 829.9 1,354.4 998.2 1,031.1 2,796.1 0.0 0.0   Pre-tax profit without non-rec. items   956 1,069 1,742 1,283 1,331 3,593 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   787 887 1,416 1,065 1,101 2,897 251 251   Interest-bearing liabilities   1.2 1.3 0.7 251 223 0.0 0.0 0.0   Balance sheet total (assets)   4,821 2,967 5,225 4,497 4,863 9,335 251 251   Net Debt   -2,897 -2,588 -3,112 -2,911 -2,978 -4,146 -251 -251     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   2,143 2,537 3,403 3,172 4,088 6,666 0.0 0.0   Gross profit growth   42.4% 18.4% 34.2% -6.8% 28.9% 63.1% -100.0% 0.0%   Employees   0 3 3 2 3 3 0 0   Employee growth %   0.0% 0.0% 0.0% -22.3% 20.2% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   4,821 2,967 5,225 4,497 4,863 9,335 251 251   Balance sheet change%   76.1% -38.5% 76.1% -13.9% 8.1% 92.0% -97.3% 0.0%   Added value   972.0 1,122.8 1,776.0 1,342.6 1,378.9 3,726.1 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   45.4% 44.3% 52.2% 42.3% 33.7% 55.9% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   26.7% 29.0% 44.0% 27.6% 30.0% 53.9% 0.0% 0.0%   ROI %   173.7% 134.5% 156.2% 98.3% 106.2% 181.2% 0.0% 0.0%   ROE %   129.5% 99.2% 117.6% 80.5% 95.2% 139.9% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   16.7% 32.4% 29.6% 24.0% 22.6% 31.0% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -298.0% -230.5% -175.2% -216.8% -216.0% -111.3% 0.0% 0.0%   Gearing %   0.2% 0.1% 0.0% 23.6% 20.3% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   422.8% 4,603.8% 5,917.8% 47.3% 30.0% 207.1% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   1.2 1.6 1.5 1.3 1.3 1.4 0.0 0.0   Current Ratio   1.2 1.4 1.4 1.3 1.3 1.4 0.0 0.0   Cash and cash equivalent   2,897.8 2,589.5 3,112.8 3,161.7 3,201.1 4,146.2 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   766.0 865.9 1,385.6 1,033.8 1,079.0 2,873.2 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 374 592 576 492 1,331 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 374 592 576 492 1,331 0 0   EBIT / employee   0 374 592 576 492 1,331 0 0   Net earnings / employee   0 277 451 428 368 999 0 0